Donate

Media center

At PATH, our global health experts are developing partnerships, new devices, and solutions to the world's most pressing health needs. Contact us to speak with one of PATH's experts today.

Contact Us

Senior Director of Marketing & Communications:
Lauren Grella

Email: media@path.org

PATH is advancing health equity around the world

April 2, 2025
Uganda launches Africa’s largest malaria vaccine rollout to date
March 25, 2025
Fewer shots, more protection: The promise of combination vaccines
March 20, 2025
How local heroes are reshaping disability care in Mozambique

Stay informed with PATH Insights

Featured Press Coverage

April 18, 2024
Millions of Girls in Africa Will Miss HPV Shots After Merck Production Problem
The New York Times
February 8, 2024
Good intentions, bad outcomes: The dangers of donated medical devices
Devex
February 12, 2024
Could new vaccines end malaria in Africa?
Al Jazeera

Recent Press Coverage

  1. Could new vaccines end malaria in Africa?
    After decades of research and development by PATH, GlaxoSmithKline, and other partners, the first doses of the RTS,S malaria vaccine began reaching children in Cameroon earlier this year.
    Published: February 2024
  2. Good intentions, bad outcomes: The dangers of donated medical devices
    COVID-19 spurred an increase in gifted medical devices, but the donations have left some facilities in under-resourced countries overwhelmed. PATH experts explain how too many facilities often lack training to use the equipment or funding to maintain it.
    Published: February 2024
  3. WHO grants prequalification to innovative polio vaccine, nOPV2, as nearly 1 billion doses are administered
    The World Health Organization granted prequalification to the novel oral polio vaccine type 2 (nOPV2), an innovative vaccine developed by a consortium of experts including PATH.
    Published: January 2024
  4. America’s Top 100 Charities
    PATH has again been named to Forbes’ annual list of the largest charities in the United States, based solely on private contributions. PATH scored 99 percent in fundraising efficiency and 89 percent in charitable commitment.
    Published: December 2023
Previous
Next

We develop evidence-based expertise and resources

Our global team leverages data and evidence to develop resources and innovations that bring good health to more people.

Explore our evidence

Join the latest discussions on health equity.

We partner with the public and private sector, government, and academia from around the world to share insightful conversations on the latest topics affecting health equity.

Explore PATH events

PATH Newsroom

Related articles

Read our latest

948 Item s
948 Item s
    Date
    From
    To
  1. Africa’s medicines regulation gains momentum with landmark Green Book listings
    PATH applauds AUDA-NEPAD and AMRH on the launch of the AMRH Green Book, a significant step forward in strengthening Africa’s regulatory systems.
    Published: April 2025
    Statement
  2. PATH Kenya and partners launch Mother-Baby Friendly Initiative Plus
    MBFI+ is a comprehensive care model to optimize feeding and save lives of SSNBs. This systems strengthening approach links kangaroo mother care, nurturing care, psychosocial support, specialized lactation support, locally appropriate human milk banking, and prevention and treatment of malnutrition as a packaged holistic intervention for mother and baby.
    Published: April 2025
    Press Release
  3. Boosting advanced-stage clinical trial capacity in East and Central Africa to combat regional epidemic threats
    The CEPI-backed Research Preparedness Program in East and Central Africa aims to bolster regional clinical trial capacity and disease outbreak readiness.
    Published: March 2025
    Press Release
  4. PATH's commitment to maternal and newborn health and nutrition at N4G Paris Summit
    Published: March 2025
    Announcement
  5. Bivalent HPV vaccine Cecolin® demonstrates strong safety and immunogenicity in low- and middle-income country populations and in various dosing schedules
    Results from a Phase 3 clinical study of Innovax’s WHO prequalified vaccine can help expand access globally and give countries another option for affordable, sustainable HPV vaccine.
    Published: March 2025
    Announcement
Next